Tumblr Puts Focus o...
Health Care: Drugs
Ligand Pharmaceuticals Inc. (LGND: NASDAQ)
$27.74 0.17 | 0.62%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 31.39M | 30.04M | 23.54M | 38.94M |
| Cost of Sales | 874.00K | 2.12M | 9.38M | 10.10M |
| Gross Operating Profit | 30.51M | 27.92M | 14.16M | 28.84M |
| Selling, General, and Administrative Expenses | 16.11M | 14.98M | 12.83M | 15.21M |
| Research & Development | 10.79M | 10.29M | 22.07M | 39.87M |
| Operating Income before D & A (EBITDA) | 3.62M | 2.65M | -20.74M | -26.24M |
| Depreciation & Amortization | 2.73M | 2.79M | 7.52M | 5.13M |
| Interest Income | 0.00 | 31.00K | 440.00K | 586.00K |
| Other Income - Net | -1.13M | 1.95M | 15.22M | 21.63M |
| Special Income / Charges | -315.00K | -2.28M | -2.75M | -442.00K |
| Total Income Before Interest Expenses (EBIT) | -560.00K | -444.00K | -15.34M | -9.60M |
| Interest Expense | 3.30M | 2.51M | 58.00K | 270.00K |
| Pre-Tax Income | -3.86M | -2.95M | -15.40M | -9.87M |
| Income Taxes | -1.19M | -13.12M | -2.62M | -1.54M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -2.67M | 10.17M | -12.79M | -8.34M |
| Net Income From Discontinued Operations | 2.15M | 3.00K | 2.41M | 6.39M |
| Net Income From Total Operations | -527.00K | 10.18M | -10.37M | -1.95M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -527.00K | 10.18M | -10.37M | -1.95M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-2.36M | 12.46M | -10.03M | -7.90M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -2.67M | 10.17M | -12.79M | -8.34M |
| Basic EPS from Continuing Ops. | -0.13 | 0.52 | -0.65 | -0.48 |
| Basic EPS from Discontinued Ops. | 0.11 | 0.00 | 0.12 | 0.36 |
| Basic EPS from Total Operations | -0.02 | 0.52 | -0.53 | -0.12 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | -0.01 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.03 | 0.52 | -0.53 | -0.12 |
| Basic Normalized Net Income/Share | -0.11 | 0.64 | -0.51 | -0.45 |
| EPS fr Continuing Ops. | -0.13 | 0.52 | -0.65 | -0.48 |
| EPS fr Discontinued Ops | 0.11 | 0.00 | 0.12 | 0.36 |
| EPS fr Total Ops. | -0.02 | 0.52 | -0.53 | -0.12 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.03 | 0.52 | -0.53 | -0.12 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.11 | 0.64 | -0.51 | -0.45 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.46 | 0.00 |
Portfolios with LGND
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserGFNN Stockdiagnostics 6
- ContributorStocks With Big Insider Buy...
- Contributor8 Stocks With Substantial I...
Latest LGND Headlines from TheStreet
- Ligand Pharmaceuticals Inc. Stock Upgraded (LGND) 05.15.13 | 05:05 am
- Ligand Pharmaceuticals Inc. Stock Downgraded (LGND) 02.18.13 | 04:02 am
- 5 Hated Stocks Set to Soar on Earnings 02.12.13 | 12:02 pm
- 5 Stocks Insiders Are Scooping Up 01.30.13 | 12:01 pm
- Top Insider Trades: BAC LGND PCRX BDBD 01.28.13 | 08:01 am
- 7 Stocks Rising on Unusual Volume 01.09.13 | 02:01 pm
- The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
11.30.12 | 05:11 am - 6 Stocks Rising on Unusual Volume 11.19.12 | 03:11 pm
- Stocks Under $10: Blossoming Biotech Play 09.25.12 | 06:09 am
- Onyx's Kyprolis Cancer Drug Approved 07.20.12 | 12:07 pm
Press Releases for LGND
- SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Ligand Pharmaceuticals Incorporated - PR Newswire 05.17.13 | 12:05 pm
- Ligand Signs Global License Agreement With Spectrum Pharmaceuticals For Captisol-Enabled® Melphalan - Business Wire 03.14.13 | 07:03 am
- Ligand Receives $1.4 Million Milestone Payment From Retrophin, Inc. - Business Wire 02.25.13 | 09:02 am
- Ligand Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Ligand To Report Fourth Quarter Results On February 13th - Business Wire 01.23.13 | 09:01 am
- Ligand Receives Equity Milestone Payment From Retrophin - Business Wire 01.09.13 | 09:01 am
- U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis - Business Wire 12.13.12 | 05:12 pm
- U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis - Business Wire 12.13.12 | 05:12 pm
- Ligand Initiates Pivotal Trial Of Captisol-Enabled®, Propylene Glycol-Free Melphalan In Patients With Multiple Myeloma - Business Wire 12.10.12 | 04:12 pm
- Ligand To Present Growth Prospects, Review Key Portfolio Assets And Introduce Financial Guidance At Analyst Day Event - Business Wire 12.04.12 | 08:12 am
Partner Headlines for LGND
- Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication - Benzinga 11.19.12 | 09:11 am
- Ligand Pharma Announces Preclinical Data for LG-7501 - Benzinga 11.13.12 | 09:11 am
- The Medicines Co. Halts MDCO-2010 - Analyst Blog - Zacks 10.08.12 | 06:10 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Netflix REITERATED Below Average and 3 Analyst-Reiterated Ratings Starting the Week - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- DJIA Weekly Review: Back-to-School Forecast Warms Up, GE and Chevron Craft Deal - Wall St. Cheat Sheet 07.22.12 | 10:07 am
- Healthcare Business Recap: Onyx's Drug Gets APPROVED, Somaxon DIVESTS Shares - Wall St. Cheat Sheet 07.20.12 | 11:07 am
- Pfizer Review ACCEPTED and 4 Stocks Enjoying 52-Week Highs - Wall St. Cheat Sheet 07.20.12 | 09:07 am
- 3M SETTLES Suit and 3 Dow Movers to Watch - Wall St. Cheat Sheet 07.19.12 | 05:07 am
- Jim Cramer Calls: Sell HP and 'Buy, Buy, Buy' These Hot Stocks Now - Wall St. Cheat Sheet 07.16.12 | 10:07 am
